Brazil has ordered the temporary suspension of the Butantan Laboratory’s dengue vaccine due to two deaths and 42 cases of serious adverse events among 500,000 recipients. The measure is precautionary while the cause is investigated.
The pilot program, aimed at people aged 15 to 29, was conducted in Maranguape, Nova Lima, and Botucatu.
The serious symptoms included abdominal pain and bleeding.
Another vaccine, Qdenga, remains available.


